Genentech prostate cancer drug fails trial (Reuters)


Reuters - An experimental prostate
cancer drug being developed by Genentech Inc. failed to prove
effective in a mid-stage trial and is not worth pursuing as a
single agent, clinical researchers said in information
presented on Saturday.

Read more...